LIXTE (LIXT) director cancels 25,000 options, receives 25,000 RSUs that vest immediately
Rhea-AI Filing Summary
Director Jason David Sawyer reported a compensation-related change in his equity awards in LIXTE BIOTECHNOLOGY HOLDINGS, INC. On April 15, 2026, he agreed with the company to cancel 25,000 options to purchase common stock with a $3.59 exercise price, which otherwise would have vested over time. In exchange, he received 25,000 restricted share units (RSUs), each representing a contingent right to one share of common stock. The RSUs were granted under the company’s 2020 Stock Incentive Plan and vested immediately upon grant, resulting in 25,000 shares of common stock held directly after the transactions. This sequence is a restructuring of equity compensation rather than an open-market buy or sell.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 25,000 shares
Net Buy
2 txns
Insider
Sawyer Jason David
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to Purchase Common Stock | 25,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 25,000 | $0.00 | $0.00 |
Holdings After Transaction:
Options to Purchase Common Stock — 0 shares (Direct);
Common Stock — 25,000 shares (Direct)
Footnotes (2)
- F1. On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on August 15, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.
- F2. The canceled Options provided for vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested.
Key Figures
Options canceled: 25,000 options
Option exercise price: $3.59 per share
RSUs granted: 25,000 RSUs
+4 more
7 metrics
Options canceled
25,000 options
Issuer disposition of options to purchase common stock on April 15, 2026
Option exercise price
$3.59 per share
Exercise price of the 25,000 canceled stock options
RSUs granted
25,000 RSUs
Granted April 15, 2026 under 2020 Stock Incentive Plan
Shares after transaction
25,000 shares
Common stock directly owned following RSU grant and vesting
Option expiration date
August 15, 2030
Expiration date of the canceled stock options
Option grant date
August 15, 2025
Original grant date of the 25,000 canceled options
RSU vesting
Immediate vesting
25,000 RSUs vested immediately upon grant on April 15, 2026
Key Terms
Stock Option Cancellation Agreement, restricted share units, 2020 Stock Incentive Plan, vesting, +1 more
5 terms
Stock Option Cancellation Agreement financial
"the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026"
2020 Stock Incentive Plan financial
"The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan."
vesting financial
"Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Disposition to issuer financial
"transaction_code_description": "Disposition to issuer""
FAQ
What did LIXT director Jason David Sawyer report in this Form 4 for LIXT?
He reported canceling 25,000 stock options and receiving 25,000 restricted share units. The RSUs vested immediately, leaving him with 25,000 shares of LIXTE Biotechnology common stock held directly after the April 15, 2026 transactions.
How many LIXT stock options were canceled in Jason David Sawyer’s Form 4?
The filing shows cancellation of 25,000 options to purchase LIXT common stock. These options carried a $3.59 exercise price and were originally granted on August 15, 2025, with vesting scheduled in stages through later calendar quarters.
What did Jason David Sawyer receive in exchange for the canceled LIXT options?
He received 25,000 restricted share units (RSUs) in exchange for the canceled options. Each RSU represents a contingent right to receive one share of LIXT common stock, granted under the 2020 Stock Incentive Plan pursuant to an award agreement.
What was the exercise price and term of the canceled LIXT stock options?
The canceled options had a $3.59 per share exercise price and an August 15, 2030 expiration date. Their vesting schedule was 50% at the effective date and the remaining 50% in 12.5% increments on December 31, 2025 and subsequent quarter-ends.
Is Jason David Sawyer’s Form 4 for LIXT an open-market stock purchase or sale?
No, the Form 4 reflects a compensation restructuring, not open-market trading. It records an issuer disposition of options back to LIXTE Biotechnology and a grant of RSUs that vested immediately into common shares held directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
